Microbiotica Raises £36M Series C to Take MB310 into Phase 2 for Ulcerative Colitis
Microbiotica has raised £36 million ($48 million) in the first close of a Series C round led by the British Business Bank. The funds will take MB310 into a blinded, placebo-controlled Phase 2 trial in ulcerative colitis to confirm results from the Phase 1b COMPOSER-1 study, with Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, Seventure Partners and all Series B investors joining the round.